Cite

HARVARD Citation

    Engelina, S. et al. (2020). Brentuximab a novel antibody therapy: real‐world use confirms efficacy and tolerability for CD30‐positive cutaneous lymphoma. British journal of dermatology. pp. 799-800. [Online]. 
  
Back to record